The Microenvironment of Pituitary Tumors-Biological and Therapeutic Implications
- PMID:31640258
- PMCID: PMC6826349
- DOI: 10.3390/cancers11101605
The Microenvironment of Pituitary Tumors-Biological and Therapeutic Implications
Abstract
The tumor microenvironment (TME) includes resident and infiltrative non-tumor cells, as well as blood and lymph vessels, extracellular matrix molecules, and numerous soluble factors, such as cytokines and chemokines. While the TME is now considered to be a prognostic tool and a therapeutic target for many cancers, little is known about its composition in pituitary tumors. This review summarizes our current knowledge of the TME within pituitary tumors and the strong interest in TME as a therapeutic target. While we cover the importance of angiogenesis and immune infiltrating cells, we also address the role of the elusive folliculostellate cells, the emerging literature on pituitary tumor-associated fibroblasts, and the contribution of extracellular matrix components in these tumors. The cases of human pituitary tumors treated with TME-targeting therapies are reviewed and emerging concepts of vascular normalization and combined therapies are presented. Together, this snapshot overview of the current literature pinpoints not only the underestimated role of TME components in pituitary tumor biology, but also the major promise it may offer for both prognosis and targeted therapeutics.
Keywords: angiogenesis; extracellular matrix; folliculostellate cells; immune infiltrate; immunotherapy; pituitary adenoma; pituitary carcinoma; pituitary tumor; treatment; tumor microenvironment.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
- Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas.Ilie MD, Vasiljevic A, Bertolino P, Raverot G.Ilie MD, et al.Endocr Rev. 2023 Mar 4;44(2):297-311. doi: 10.1210/endrev/bnac024.Endocr Rev. 2023.PMID:36269838Review.
- Exploring the role of the tumor microenvironment in refractory pituitary tumor pathogenesis.Ben-Shlomo A.Ben-Shlomo A.Pituitary. 2023 Jun;26(3):263-265. doi: 10.1007/s11102-023-01301-y. Epub 2023 Mar 4.Pituitary. 2023.PMID:36870010Review.
- Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment.Melo V, Bremer E, Martin JD.Melo V, et al.Front Cell Dev Biol. 2022 May 30;10:908389. doi: 10.3389/fcell.2022.908389. eCollection 2022.Front Cell Dev Biol. 2022.PMID:35712656Free PMC article.Review.
- The tumour microenvironment of pituitary neuroendocrine tumours.Marques P, Grossman AB, Korbonits M.Marques P, et al.Front Neuroendocrinol. 2020 Jul;58:100852. doi: 10.1016/j.yfrne.2020.100852. Epub 2020 Jun 15.Front Neuroendocrinol. 2020.PMID:32553750Review.
- Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy.Tapoi DA, Popa ML, Tanase C, Derewicz D, Gheorghișan-Gălățeanu AA.Tapoi DA, et al.Cancers (Basel). 2023 Nov 6;15(21):5301. doi: 10.3390/cancers15215301.Cancers (Basel). 2023.PMID:37958474Free PMC article.Review.
Cited by
- The immune microenviroment in somatotropinomas: from biology to personalized and target therapy.Chiloiro S, De Marinis L.Chiloiro S, et al.Rev Endocr Metab Disord. 2023 Apr;24(2):283-295. doi: 10.1007/s11154-022-09782-1. Epub 2023 Jan 20.Rev Endocr Metab Disord. 2023.PMID:36658300Free PMC article.Review.
- Pituitary Tumors: New Insights into Molecular Features, Diagnosis and Therapeutic Targeting.Fedele M.Fedele M.Cancers (Basel). 2021 Apr 3;13(7):1697. doi: 10.3390/cancers13071697.Cancers (Basel). 2021.PMID:33916675Free PMC article.
- Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?Sol B, de Filette JMK, Awada G, Raeymaeckers S, Aspeslagh S, Andreescu CE, Neyns B, Velkeniers B.Sol B, et al.Eur J Endocrinol. 2021 Jan;184(1):K1-K5. doi: 10.1530/EJE-20-0151.Eur J Endocrinol. 2021.PMID:33112279Free PMC article.
- Vascular Normalization: A New Window Opened for Cancer Therapies.Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N, Guo X.Yang T, et al.Front Oncol. 2021 Aug 12;11:719836. doi: 10.3389/fonc.2021.719836. eCollection 2021.Front Oncol. 2021.PMID:34476218Free PMC article.Review.
- Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.Yang Q, Zhu W, Gong H.Yang Q, et al.Front Immunol. 2023 Apr 3;14:1148483. doi: 10.3389/fimmu.2023.1148483. eCollection 2023.Front Immunol. 2023.PMID:37077919Free PMC article.
References
- Raverot G., Burman P., McCormack A., Heaney A., Petersenn S., Popovic V., Trouillas J., Dekkers O.M. The European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the Management of Aggressive Pituitary Tumours and Carcinomas. Eur. J. Endocrinol. 2018;178:G1–G24. doi: 10.1530/EJE-17-0796. - DOI - PubMed
- Asa S.L., Casar-Borota O., Chanson P., Delgrange E., Earls P., Ezzat S., Grossman A., Ikeda H., Inoshita N., Karavitaki N., et al. From Pituitary Adenoma to Pituitary Neuroendocrine Tumor (PitNET): An International Pituitary Pathology Club Proposal. Endocr. Relat. Cancer. 2017;24:C5–C8. doi: 10.1530/ERC-17-0004. - DOI - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources